{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T15:03:50Z","timestamp":1791471830772,"version":"4.3.4"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2025,3,8]],"date-time":"2025-03-08T00:00:00Z","timestamp":1741392000000},"content-version":"vor","delay-in-days":4,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,3,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Increased carbapenem prescribing has contributed to rising rates of carbapenem-resistant bacterial pathogens. Although antimicrobial stewardship efforts that facilitate de-escalation of carbapenems to alternative agents can minimize unnecessary exposure, clinicians may be hesitant to de-escalate therapy due to concerns for potentially compromising patient outcomes. A literature search was performed to characterize carbapenem de-escalation strategies and assess associated patient outcomes. A total of 228 articles were screened on PubMed, and 15 studies that examine the de-escalation of carbapenems to non-carbapenem alternatives were identified for inclusion. The studies primarily included non\u2013critically ill and immunocompetent adults involving over 5000 patients receiving carbapenem therapy for a variety of infections, most commonly urinary tract infections, pneumonia, and skin and soft tissue infections. Twelve of 15 studies reported carbapenem de-escalation as part of their antimicrobial stewardship programme (ASP) initiatives. Overall, carbapenem de-escalation led to a reduction in carbapenem use by 2 to 5 days and was not associated with negative outcomes (higher rates of clinical failure or mortality) compared with the continuation groups. Baseline characteristics of patient age, comorbidities, severity of illness, infection site and pathogen were not consistently described or balanced between groups, which may bias results in favour of de-escalation. Identification of which patients to consider for antibiotic de-escalation is nuanced and requires careful consideration of complex patient history, infection type, clinical stability and microbiology results. Although findings support carbapenem de-escalation as a promising ASP strategy, more high-quality studies are needed to more definitely elucidate the impact of carbapenem de-escalation on clinical outcomes.<\/jats:p>","DOI":"10.1093\/jacamr\/dlaf022","type":"journal-article","created":{"date-parts":[[2025,3,8]],"date-time":"2025-03-08T17:50:21Z","timestamp":1741456221000},"source":"Crossref","is-referenced-by-count":17,"title":["Carbapenem de-escalation as an antimicrobial stewardship strategy: a narrative review"],"prefix":"10.1093","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-7628-9852","authenticated-orcid":false,"given":"Adriana","family":"Gardner","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Huntington Health , Pasadena, CA ,","place":["USA"]},{"name":"Department of Clinical Pharmacy, University of Southern California Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences , Los Angeles, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Nieberg","sequence":"additional","affiliation":[{"name":"Department of Medicine\u2014Infectious Diseases, Huntington Health , Pasadena, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6063-6217","authenticated-orcid":false,"given":"George","family":"Sakoulas","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Sharp Rees Stealy Medical Group , San Diego, CA ,","place":["USA"]},{"name":"University of California San Diego School of Medicine , La Jolla, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3302-1409","authenticated-orcid":false,"given":"Annie","family":"Wong-Beringer","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Huntington Health , Pasadena, CA ,","place":["USA"]},{"name":"Department of Clinical Pharmacy, University of Southern California Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences , Los Angeles, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,3,8]]},"reference":[{"key":"2025030817501504700_dlaf022-B1","author":"World Health Organization"},{"key":"2025030817501504700_dlaf022-B2","doi-asserted-by":"publisher","first-page":"dlac048","DOI":"10.1093\/jacamr\/dlac048","article-title":"Comparison of the global prevalence and trend of human intestinal carriage of ESBL-producing Escherichia coli between healthcare and community settings: a systematic review and meta-analysis","volume":"4","author":"Bezabih","year":"2022","journal-title":"JAC Antimicrob Resist"},{"key":"2025030817501504700_dlaf022-B3","author":"CDC"},{"key":"2025030817501504700_dlaf022-B4","doi-asserted-by":"publisher","first-page":"e368","DOI":"10.1016\/S1473-3099(18)30296-2","article-title":"Quantifying drivers of antibiotic resistance in humans: a systematic review","volume":"18","author":"Chatterjee","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"2025030817501504700_dlaf022-B5","doi-asserted-by":"publisher","first-page":"e893","DOI":"10.1016\/S2542-5196(21)00280-1","article-title":"Global antibiotic consumption and usage in humans, 2000-18: a spatial modelling study","volume":"5","author":"Browne","year":"2021","journal-title":"Lancet Planet Health"},{"key":"2025030817501504700_dlaf022-B6","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1080\/21505594.2015.1134072","article-title":"Bloodstream infections in the intensive care unit","volume":"7","author":"Bassetti","year":"2016","journal-title":"Virulence"},{"key":"2025030817501504700_dlaf022-B7","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1007\/s00134-022-06944-2","article-title":"Epidemiology and outcomes of hospital-acquired bloodstream infections in intensive care unit patients: the EUROBACT-2 international cohort study","volume":"49","author":"Tabah","year":"2023","journal-title":"Intensive Care Med"},{"key":"2025030817501504700_dlaf022-B8","doi-asserted-by":"publisher","first-page":"CD007934","DOI":"10.1002\/14651858.CD007934.pub3","article-title":"De-escalation of antimicrobial treatment for adults with sepsis, severe sepsis or septic shock","volume":"3","author":"Gomes Silva","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"2025030817501504700_dlaf022-B9","doi-asserted-by":"publisher","first-page":"e13245","DOI":"10.1111\/ijcp.13245","article-title":"Antibiotic de-escalation in patients with pneumonia in the intensive care unit: a systematic review and meta-analysis","volume":"72","author":"Ambaras Khan","year":"2018","journal-title":"Int J Clin Pract"},{"key":"2025030817501504700_dlaf022-B10","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/S1473-3099(16)00065-7","article-title":"Current evidence on hospital antimicrobial stewardship objectives: a systematic review and meta-analysis","volume":"16","author":"Schuts","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"2025030817501504700_dlaf022-B11","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1093\/cid\/civ1199","article-title":"A systematic review of the definitions, determinants, and clinical outcomes of antimicrobial de-escalation in the intensive care unit","volume":"62","author":"Tabah","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2025030817501504700_dlaf022-B12","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/s10096-018-3408-2","article-title":"Meropenem antimicrobial stewardship program: clinical, economic, and antibiotic resistance impact","volume":"38","author":"Garc\u00eda-Rodr\u00edguez","year":"2019","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2025030817501504700_dlaf022-B13","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1111\/ped.14703","article-title":"Acceptance and outcome of interventions in a meropenem de-escalation antimicrobial stewardship program in pediatrics","volume":"63","author":"Rungsitsathian","year":"2021","journal-title":"Pediatr Int"},{"key":"2025030817501504700_dlaf022-B14","doi-asserted-by":"publisher","first-page":"e00736-17","DOI":"10.1128\/AAC.00736-17","article-title":"Impact of a carbapenem antimicrobial stewardship program on patient outcomes","volume":"61","author":"Seah","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2025030817501504700_dlaf022-B15","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1086\/673976","article-title":"Carbapenem de-escalation therapy in a resource-limited setting","volume":"34","author":"Apisarnthanarak","year":"2013","journal-title":"Infect Control Hosp Epidemiol"},{"key":"2025030817501504700_dlaf022-B16","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1093\/jac\/dku479","article-title":"Safety and clinical outcomes of carbapenem de-escalation as part of an antimicrobial stewardship programme in an ESBL-endemic setting","volume":"70","author":"Lew","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"2025030817501504700_dlaf022-B17","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s40545-023-00599-0","article-title":"Clinical impact of multidisciplinary carbapenem stewardship interventions: a retrospective cohort study","volume":"16","author":"Ramadas","year":"2023","journal-title":"J Pharm Policy Pract"},{"key":"2025030817501504700_dlaf022-B18","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/j.jiph.2019.09.014","article-title":"Pharmacist recommendations for carbapenem de-escalation in urinary tract infection within an antimicrobial stewardship program","volume":"13","author":"Sadyrbaeva-Dolgova","year":"2020","journal-title":"J Infect Public Health"},{"key":"2025030817501504700_dlaf022-B19","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.ijid.2019.04.034","article-title":"Clinical outcomes of carbapenem de-escalation regardless of microbiological results: a propensity score analysis","volume":"85","author":"Sadyrbaeva-Dolgova","year":"2019","journal-title":"Int J Infect Dis"},{"key":"2025030817501504700_dlaf022-B20","doi-asserted-by":"publisher","first-page":"330","DOI":"10.3390\/antibiotics11030330","article-title":"Impact of the acceptance of the recommendations made by a meropenem stewardship program in a university hospital: a pilot study","volume":"11","author":"Alba Fernandez","year":"2022","journal-title":"Antibiotics (Basel)"},{"key":"2025030817501504700_dlaf022-B21","doi-asserted-by":"publisher","first-page":"3041","DOI":"10.1007\/s10096-012-1662-2","article-title":"Utility and safety of procalcitonin in an antimicrobial stewardship program (ASP) in patients with malignancies","volume":"31","author":"Liew","year":"2012","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2025030817501504700_dlaf022-B22","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1007\/s11845-016-1504-9","article-title":"Targeted de-escalation rounds may effectively and safely reduce meropenem use","volume":"186","author":"Ni Riain","year":"2017","journal-title":"Ir J Med Sci"},{"key":"2025030817501504700_dlaf022-B23","doi-asserted-by":"publisher","first-page":"e13693","DOI":"10.1111\/ijcp.13693","article-title":"Impact of the multidisciplinary antimicrobial stewardship team intervention focusing on carbapenem de-escalation: a single-centre and interrupted time series analysis","volume":"75","author":"Suzuki","year":"2021","journal-title":"Int J Clin Pract"},{"key":"2025030817501504700_dlaf022-B24","doi-asserted-by":"publisher","first-page":"19","DOI":"10.47102\/annals-acadmedsg.V44N1p19","article-title":"Safety and effectiveness of improving carbapenem use via prospective review and feedback in a multidisciplinary antimicrobial stewardship programme","volume":"44","author":"Teng","year":"2015","journal-title":"Ann Acad Med Singap"},{"key":"2025030817501504700_dlaf022-B25","doi-asserted-by":"publisher","first-page":"14501","DOI":"10.1038\/s41598-023-41710-4","article-title":"Impact of prolonged carbapenem use-focused antimicrobial stewardship on antimicrobial consumption and factors affecting acceptance of recommendations: a quasi-experimental study","volume":"13","author":"Yoo","year":"2023","journal-title":"Sci Rep"},{"key":"2025030817501504700_dlaf022-B26","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/j.jcrc.2009.11.007","article-title":"De-escalation after empirical meropenem treatment in the intensive care unit: fiction or reality?","volume":"25","author":"De Waele","year":"2010","journal-title":"J Crit Care"},{"key":"2025030817501504700_dlaf022-B27","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1080\/14787210.2016.1233814","article-title":"Implementation of rapid diagnostics with antimicrobial stewardship","volume":"14","author":"Minejima","year":"2016","journal-title":"Expert Rev Anti Infect Ther"},{"key":"2025030817501504700_dlaf022-B28","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1007\/s00134-020-06111-5","article-title":"Antimicrobial de-escalation in the critically ill patient and assessment of clinical cure: the DIANA study","volume":"46","author":"De Bus","year":"2020","journal-title":"Intensive Care Med"},{"key":"2025030817501504700_dlaf022-B29","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1001\/jama.2018.12163","article-title":"Effect of piperacillin-tazobactam vs meropenem on 30-day mortality for patients with E. coli or Klebsiella pneumoniae bloodstream infection and ceftriaxone resistance: a randomized clinical trial","volume":"320","author":"Harris","year":"2018","journal-title":"JAMA"}],"container-title":["JAC-Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jacamr\/article-pdf\/7\/2\/dlaf022\/62342178\/dlaf022.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jacamr\/article-pdf\/7\/2\/dlaf022\/62342178\/dlaf022.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,8]],"date-time":"2025-03-08T17:50:23Z","timestamp":1741456223000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jacamr\/article\/doi\/10.1093\/jacamr\/dlaf022\/8063828"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,4]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,3,4]]}},"URL":"https:\/\/doi.org\/10.1093\/jacamr\/dlaf022","relation":{},"ISSN":["2632-1823"],"issn-type":[{"value":"2632-1823","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,4]]},"published":{"date-parts":[[2025,3,4]]},"article-number":"dlaf022"}}